Competitor Analysis: EGF-R Agonists and Antagonists

Date: September 22, 2011
Pages: 73
US$ 533.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Competitor Analysis: EGF-R Agonists and Antagonists
The present Competitive Intelligence Report about EGF-R agonists and antagonists provides a competitor evaluation in the field of epidermal growth factor receptor (EGF-R; ErbB1) targeting molecules for wound healing or treatment of cancer as of September 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The human epidermal growth factor receptor (HER) family members include EGFR (erbB1), HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4) that are structurally related, and all except HER3 contain intracellular tyrosine kinase (tk) domain. All of the HER members, except HER2, bind to extracellular ligands.

EGFR, a valid target in many epithelial malignancies, is a transmembrane protein with an extracellular ligand binding domain joined to an intracellular tyrosine kinase domain. Activation of EGFR induces a cascade of downstream signaling through several pathways, such as mitogenac tivated protein kinase (MAPK) and PI3-kinase / Akt/mTOR, resulting in cellular proliferation, differentiation, survival, motility, adhesion, and repair. EGFR is overexpressed or abnormally activated in several epithelial malignancies. Several antibodies targeting EGF-R and small molecules inhibiting the EGF-R tyrosine kinase have been approved and are used for treatment of colorectal cancer, squamous cell cancer of the head & neck or pancreatic cancer, respectively.

The report includes a compilation of current active projects in research and development of molecules targeting the EGF receptor. In addition, the report lists company-specific R&D pipelines of EGF-R targeting small molecules, antibodies, proteins, cells and vaccines. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

  • 2010 Sales of EGF-R Antagonists
  • EGF-R Agonists
  • Erbitux Pipeline
  • Vectibix Pipeline
  • Tarceva Pipeline
  • Biologics as EGF-R Antagonists
  • Selective EGF Receptor Antagonists
  • Dual EGF-R and Her2 Receptor Antagonists
  • Pan-ErbB (pan-Her) Receptor Antagonists
  • Multi-Target EGF-R Antagonists
  • Others
  • Corporate EGF-R Agonist and Antagonist R&D Pipelines
  • About La Merie

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Skip to top

Ask Your Question

Competitor Analysis: EGF-R Agonists and Antagonists
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: